The prevailing theory on Alzheimer’s pathogenesis is moving inexorably away from the amyloid hypothesis and towards neuroinflammation. Amyloid is damage done, need to back the cognitive clock up to the real triggers…no way does the risk reward work out for these new drugs; intracranial bleed should be a full stop no by FDA when considering approval.

Chemokine signaling is at the heart of the process and temporally way ahead of tau/amyloid…much better target IMHO.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314046/